IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by KBC Group NV

KBC Group NV decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 41.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 365,841 shares of the medical research company's stock after selling 259,357 shares during the quarter. KBC Group NV owned approximately 0.20% of IQVIA worth $86,694,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. 1832 Asset Management L.P. raised its holdings in IQVIA by 472.3% in the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company's stock valued at $96,487,000 after acquiring an additional 376,595 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of IQVIA in the 2nd quarter valued at $70,610,000. Impax Asset Management Group plc lifted its position in shares of IQVIA by 19.3% during the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company's stock worth $344,998,000 after purchasing an additional 264,555 shares during the last quarter. Canada Pension Plan Investment Board grew its stake in shares of IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company's stock worth $719,634,000 after purchasing an additional 211,653 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its stake in IQVIA by 285.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company's stock valued at $56,783,000 after buying an additional 198,808 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Performance

Shares of IQVIA stock traded down $6.76 during trading hours on Thursday, hitting $204.75. 1,311,991 shares of the company were exchanged, compared to its average volume of 1,118,963. The business has a 50-day moving average of $228.86 and a 200-day moving average of $228.77. IQVIA Holdings Inc. has a 1 year low of $200.20 and a 1 year high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a market capitalization of $37.16 billion, a price-to-earnings ratio of 27.75, a P/E/G ratio of 2.20 and a beta of 1.51.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company's stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on IQV. Jefferies Financial Group cut IQVIA from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 5th. Redburn Atlantic initiated coverage on shares of IQVIA in a report on Monday, October 14th. They set a "buy" rating and a $276.00 price objective on the stock. UBS Group upped their target price on shares of IQVIA from $295.00 to $300.00 and gave the company a "buy" rating in a report on Tuesday, July 23rd. Finally, Evercore ISI cut their price target on shares of IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $259.13.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.